Available by Consultation

These options are available only through provider consultation in patient-specific circumstances. They are not standard retail products.

Compounded medications are not FDA-approved

Availability may change with regulatory posture

Eligibility determined by clinician

Compounded Semaglutide

InjectableWeight Loss

Semaglutide injection 0.25–2.5 mg/mL

A compounded semaglutide option available only through provider consultation in limited patient-specific circumstances. Compounded medications are not FDA-approved. FDA has tightened 503A compounding rules for GLP-1 products.

BPC-157

InjectablePeptide Therapy

BPC-157 (Body Protection Compound-157)

A research-stage peptide available only through provider consultation. Not FDA-approved. Listed on FDA 503A Category 2 list. Human clinical data remains limited.

These products are compounded by licensed pharmacies and are not FDA-approved. Human clinical evidence varies by product and may be limited or preliminary. Regulatory status, compounding availability, and FDA enforcement posture may change. Medical services are provided by independent licensed clinicians using the Varus platform. Varus does not provide medical advice, diagnosis, or treatment.